Lung transplantation: past, present, and future.
Lung transplantation (LTx) is an established therapy for end-stage lung disease (ESLD). Survival after LTx is limited by infection and rejection, particularly bronchiolitis obliterans syndrome (BOS). New techniques with the potential to increase donor lung supply and prevent rejection continue to evolve. These developments hold promise for improved outcomes for a greater number of patients.
Yun
J J
JJ
Department of Thoracic and Cardiovascular Surgery, Cleveland Clinic, Cleveland, OH, USA.
Mason
D P
DP
D000818:Animals; D001989:Bronchiolitis Obliterans / Q000276:immunology; D046148:Donor Selection; D006801:Humans; D008171:Lung Diseases / Q000601:surgery*; D016040:Lung Transplantation / Q000009:adverse effects / Q000276:immunology / Q000401:mortality / Q000639:trends*; D018579:Patient Selection; D012307:Risk Factors; D016019:Survival Analysis; D013577:Syndrome; D009927:Tissue and Organ Procurement / Q000639:trends; D014184:Transplantation, Homologous / Q000639:trends; D016896:Treatment Outcome